# AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

> **NCT05522894** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 80 (estimated)

## Conditions studied

- Unresectable Esophageal Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** AK104
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05522894
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522894, "AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05522894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*